antibody production antibody production
play

6/19/2015 IMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM Massimo Mangiola, Ph.D. Director, Special Services Rhode Island Blood Center LEARN Webinars: Management of TRALI June 23, 2015 2:00 3:30 pm (EDT) ANTIBODY PRODUCTION

0 downloads 3 Views 1,34 MB Size Report
  1. 6/19/2015 IMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM Massimo Mangiola, Ph.D. Director, Special Services Rhode Island Blood Center LEARN Webinars: Management of TRALI June 23, 2015 2:00 – 3:30 pm (EDT) ANTIBODY PRODUCTION ANTIBODY PRODUCTION 1

  2. 6/19/2015 ANTIBODY PRODUCTION ANTIBODY RESPONSE ANTIBODY RESPONSE 2

  3. 6/19/2015 ANTIBODY CLASSES ANTIBODY CLASSES ANTIBODY CLASSES 3

  4. 6/19/2015 WHAT TRIGGERS THE IMMUNE SYSTEM TO GENERATE HLA ANTIBODIES ? WHAT CAN INDUCE ANTIBODY PRODUCTION ? TRANSPLANT TRANSFUSION PREGNANCY WHAT IS NON-SELF ON A HLA MOLECULE ? 4

  5. 6/19/2015 WHAT IS NON-SELF ON A HLA MOLECULE ? WHAT IS NON-SELF ? HOW IS NON-SELF ON A HLA MOLECULE RECOGNIZED ? 5

  6. 6/19/2015 HOW IS NON-SELF ON A HLA MOLECULE RECOGNIZED ? ANTIBODY ½ LIFE PREGNANCY ANTIBODY 6

  7. 6/19/2015 HOW CAN HLA ANTIBODIES CAUSES TRALI ? 7

  8. 6/19/2015 THE PERFECT “STORM” THE PERFECT “STORM” About 9 m m THE PERFECT “STORM” 8

  9. 6/19/2015 THE PERFECT “STORM” Lumen: 5.5 m m Distance from alveolus: 0.5 m m THE PERFECT “STORM” Lumen: 5.5 m m Distance from alveolus: 0.5 m m THE PERFECT “STORM” 9

  10. 6/19/2015 HLA ANTIBODIES & TRALI ANTIBODY-DEPENDENT MODEL Class II HLA antibody or Fc g R Class I HLA antibody HLA ANTIBODIES & TRALI ANTIBODY-INDEPENDENT MODEL (2 hit theory) 1 st EVENT (1 ST HIT) Recipient predisposing clinical condition resulting in the sequestration of primed neutrophils in the lungs (cytokines promote priming and adherence of neutrophils). 2 nd EVENT (2 ND HIT) Transfusion of blood product(s) carrying a biological substance able to activate primed neutrophils (i.e. leukocyte antibodies, DAMPs, LysoPC, etc.) HOW CAN HLA ANTIBODIES BE DETECTED IN THE LABORATORY? 10

  11. 6/19/2015 HLA ANTIBODY DETECTION SOLID PHASE ANTIBODY LUMINEX SOLID PHASE SCREENING ANTIBODY SCREEN ASSAY ELISA-BASED ANTIBODY SCREENING ™DONORSCREEN HLA ASSAY ™DONORSCREEN HLA ASSAY LUMINEX SCREENING ELISA SCREENING INCUBATION WASH INCUBATION WASH DETECTION INCUBATION STOP 11

  12. 6/19/2015 HLA ANTIBODY DETECTION SOLID PHASE ANTIBODY LUMINEX SOLID PHASE SCREENING ANTIBODY SCREEN ASSAY ELISA-BASED ANTIBODY SCREENING ™DONORSCREEN HLA ASSAY ™DONORSCREEN HLA ASSAY RHODE ISLAND BLOOD CENTER EXPERIENCE TRALI MITIGATION TIMELINE AABB Standard 5.4.1.2 to be ABC releases statement to implemented encourage considering TRALI reduction strategies First AABB bulletin on TRALI ~1998 - 2008 - 2002 2004 2006 2016 2002 present Luminex ELISA CDC Solid Phase (DonorScreen HLA) Screening 12

  13. 6/19/2015 THE RIBC EXPERIENCE 0-20(0.5%) RIBC Donor Population Age groups High volume plasma donors >60 21-40 36,952 previously pregnant female 21% 22% 41-60 56.5% Data Range: 2008 to April 2015 THE RIBC EXPERIENCE 40000 36952 30000 TOTAL NEGATIVE 23823 20000 POSITIVE 13129 10000 (35.5%) 0 FEMALE BLOOD DONORS Data Range: 2008 to April 2015 THE RIBC EXPERIENCE Negative >60 41-60 (17.3%) (59.3%) Positive 21-40 (23%) 0-20 High volume plasma donors 36,952 previously pregnant female (0.4%) 23, 823 negative for HLA antibodies 13,129 positive for HLA antibodies Data Range: 2008 to April 2015 13

  14. 6/19/2015 THE RIBC EXPERIENCE Negative 41-60 >60 (36.9%) (28.8%) Positive 21-40 (36.5%) 0-20 (28%) High volume plasma donors Rate of positive donors Normalized data by age group Data Range: 2008 to April 2015 SUMMARY TRALI is the leading cause of transfusion-related fatalities HLA antibodies can induce TRALI in sensitized recipients HLA pregnancy antibodies can disappear overtime HLA antibodies detection can be done by Luminex or ELISA solid phase Donor age is NOT a factor; number of pregnancies may be more relevant RIBC TRALI Mitigation program started around 1998. Since then, only ~400 TRALI investigation have been done. Of these, only 5% had HLA antibodies in the donor sample and just a handful of cases may be due to reverse-TRALI. CONCLUSION Mitigation proves to be effective in reducing TRALI occurrence An action plan must be in place by October 1 st , 2016 14

  15. 6/19/2015 CONCLUSION Mitigation proves to be effective in reducing TRALI occurrence An action plan must be in place by October 1 st , 2016 CONCLUSION Should positive donors be re-screened and when ? If a donor is still positive after re-screen, should testing be repeated ? testing frequency ? for how long to re-test ? Because age of donor does not seems to be a factor, changes in recruitment strategies may not help in decreasing the positive rate. Can PAS help us in re-entry of some aphaeresis donor ? How do we establish which donor to re-entry with PAS ? Should we consider transfusion risk ? What about HNA antibody screening ? What else ? LEARN Webinars: Management of TRALI May 21, 2015 2:00 – 3:30 pm (EDT) 15

Recommend Documents


antibody specificity what s the problem
Antibody Specificity: What's the

Antibody Specificity: What's the problem? The Antibody Society Webcast

validation of commercial tool antibodies
Validation of Commercial tool

Validation of Commercial tool Antibodies The Antibody Society Webcast series

validation of commercial tool antibodies
Validation of Commercial tool

Validation of Commercial tool Antibodies The Antibody Society Webcast series

t cell mediated immunity
T cell-mediated immunity T

T cell-mediated immunity T cell-mediated immunity Antibody B cells help

immunoth rapie immunoth rapie pembrolizumab
Immunothrapie Immunothrapie

Soire Immunothrapie ROHLim 21 septembre 2016 Immunothrapie Immunothrapie

the product datasheet formulation and antibody performance
The Product Datasheet- Formulation and

The Product Datasheet- Formulation and Antibody Performance The Antibody

antibody generation system
Antibody Generation System Maturation,

Antibody Generation System Maturation, Selection and Production in CHO Cells

bvd testing the disease the two tests
BVD Testing The Disease The Two Tests

BVD Testing The Disease The Two Tests 1. BVD Antibody 2. BVD

validation of commercial tool antibodies
Validation of Commercial tool

Validation of Commercial tool Antibodies The Antibody Society Webcast series

sea lane human antibody libraries sea lane human antibody
Sea Lane Human Antibody Libraries Sea

Sea Lane Human Antibody Libraries Sea Lane Human Antibody Libraries ConCIRT

childhood blindness due to rop childhood blindness due to
Childhood blindness due to ROP

Childhood blindness due to ROP Childhood blindness due to ROP Number of blind

trilogy e ev30 v300 evolution of care
Trilogy E EV30 V300 evolution of care

Trilogy E EV30 V300 evolution of care simple, portable, reliable, adaptable

non infectious pulmonary complications diffuse alveolar
Noninfectious Pulmonary

Noninfectious Pulmonary Complications: Diffuse Alveolar Hemorrhage and

miragen therapeutics
miRagen Therapeutics NASDAQ: MGEN May

Restoring Biological Harmony for Patients with Debilitating Disease Restoring

forum
Forum 4/24/2019 Do Not to Teach

Level 1 Graduates Forum 4/24/2019 Do Not to Teach Comfortable pause=Control

covid 19 critical care management june 4th 2020
COVID-19 Critical Care Management

COVID-19 Critical Care Management June 4th, 2020 Anthony Massaro, MD

a massive peripheral ossifying fibroma uncommon
A Massive Peripheral Ossifying

A Massive Peripheral Ossifying FibromaUncommon Presentation of a Common Lesion

an introduction to mastitis what is mastitis
An Introduction to Mastitis What is

An Introduction to Mastitis What is Mastitis? Inflammation of the mammary

the mooresville hydrail initiative the mooresville
THE MOORESVILLE HYDRAIL

THE WORLD TRANSITION TO HYDRAIL AND ITS IMPROBABLE ORIGINS presented to the US

case study 1
Case Study #1 Andrea Bakker RN, PCCN

Case Study #1 Andrea Bakker RN, PCCN Patient Data 62 Year old Female

bill tyrrell dvm dacvim
Bill Tyrrell, DVM, DACVIM- Stressful

CVCA-Cardiac Care for Pets 2/3/2019 Feline Diagnostics (there is no one

simple monitoring of ultrafine particles
Simple monitoring of ultrafine

Simple monitoring of ultrafine particles Henk Goossens June 2011 Ultrafines